Skip to main content
Top
Published in: Indian Journal of Gastroenterology 5/2023

23-08-2023 | Portal Vein Thrombosis | Editorial

Thrombophilia testing in splanchnic venous thrombosis: Decoding a conundrum

Authors: Akash Shukla, Sidharth Harindranath

Published in: Indian Journal of Gastroenterology | Issue 5/2023

Login to get access

Excerpt

We read with great interest the article by Giri et al. analyzing the prevalence of acquired and inherited thrombophilia among Indian patients with non-cirrhotic portal vein thrombosis (PVT) and Budd-Chiari syndrome (BCS). The authors reported that the thrombophilia profile in Indian patients with abdominal vein thrombosis is different as compared to the west with a lower prevalence of prothrombotic conditions in patients with BCS. At least one prothrombotic condition was seen in 46.2% (28.7–63.7) of patients with PVT and 44.9% (37.3–60.7) of patients with BCS. Most common condition seen in patients with PVT was hyperhomocystinemia, whereas, in patients with BCS, protein C deficiency was the most common [1]. This study sheds light on the contentious topic of thrombophilia testing in patients with splanchnic venous thrombosis and ends up generating many questions while answering a few. …
Literature
4.
go back to reference Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004–8.CrossRefPubMedPubMedCentral Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004–8.CrossRefPubMedPubMedCentral
5.
go back to reference Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–6.CrossRefPubMed Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–6.CrossRefPubMed
6.
go back to reference Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343:1535–6.CrossRefPubMed Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343:1535–6.CrossRefPubMed
7.
go back to reference Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377–9.CrossRefPubMedPubMedCentral Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377–9.CrossRefPubMedPubMedCentral
8.
go back to reference Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed
9.
go back to reference Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2021;15:531–67.CrossRefPubMed Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2021;15:531–67.CrossRefPubMed
10.
go back to reference Rodríguez-Leal GA, Morán S, Corona-Cedillo R, Brom-Valladares R. Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient. World J Hepatol. 2014;6:532–7.CrossRefPubMedPubMedCentral Rodríguez-Leal GA, Morán S, Corona-Cedillo R, Brom-Valladares R. Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient. World J Hepatol. 2014;6:532–7.CrossRefPubMedPubMedCentral
11.
go back to reference Parkash O, Khan A, Hamid S. Clinical characteristics and out- come of Budd-Chiari syndrome at a tertiary care hospital in Pakistan. J Coll Phys Surg-Pak JCPSP. 2017;27:301–4. Parkash O, Khan A, Hamid S. Clinical characteristics and out- come of Budd-Chiari syndrome at a tertiary care hospital in Pakistan. J Coll Phys Surg-Pak JCPSP. 2017;27:301–4.
12.
go back to reference Tasneem AA, Soomro GB, Abbas Z, Luck NH, Hassan SM. Clinical presentation and predictors of survival in patients with Budd Chiari syndrome: experience from a tertiary care hospital in Pakistan. JPMA J Pak Med Assoc. 2015;65:120–4.PubMed Tasneem AA, Soomro GB, Abbas Z, Luck NH, Hassan SM. Clinical presentation and predictors of survival in patients with Budd Chiari syndrome: experience from a tertiary care hospital in Pakistan. JPMA J Pak Med Assoc. 2015;65:120–4.PubMed
13.
go back to reference Westbrook RH, Lea NC, Mohamedali AM, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012;18:819–27.CrossRefPubMed Westbrook RH, Lea NC, Mohamedali AM, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012;18:819–27.CrossRefPubMed
14.
go back to reference Fan J, Wang Q, Luo B, et al. Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: a hospital-based observational study. J Gastroenterol Hepatol. 2020;35:1215–22.CrossRefPubMed Fan J, Wang Q, Luo B, et al. Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: a hospital-based observational study. J Gastroenterol Hepatol. 2020;35:1215–22.CrossRefPubMed
15.
go back to reference Nowak-Göttl U, Junker R, Kreuz W, et al. Childhood thrombophilia study group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97:858–62.CrossRefPubMed Nowak-Göttl U, Junker R, Kreuz W, et al. Childhood thrombophilia study group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97:858–62.CrossRefPubMed
Metadata
Title
Thrombophilia testing in splanchnic venous thrombosis: Decoding a conundrum
Authors
Akash Shukla
Sidharth Harindranath
Publication date
23-08-2023
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 5/2023
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-023-01443-8

Other articles of this Issue 5/2023

Indian Journal of Gastroenterology 5/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine